These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 25910372)

  • 1. Temporary placement of a paclitaxel or rapamycin-eluting stent is effective to reduce stenting induced inflammatory reaction and scaring in benign cardia stricture models.
    Wang L; Zhu YQ; Cheng YS; Cui WG; Chen NW
    Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():69-74. PubMed ID: 25910372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodegradable rapamycin-eluting nano-fiber membrane-covered metal stent placement to reduce fibroblast proliferation in experimental stricture in a canine model.
    Zhu YQ; Cui WG; Cheng YS; Chang J; Chen NW; Yan L; Li MH
    Endoscopy; 2013 Jun; 45(6):458-68. PubMed ID: 23580413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of biodegradable paclitaxel-eluting nanofibre-covered metal stents for the treatment of benign cardia stricture in an experimental model.
    Zhu YQ; Cui WG; Cheng YS; Chang J; Chen NW; Yan L
    Br J Surg; 2013 May; 100(6):784-93. PubMed ID: 23553755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporary self-expanding cardia stents for the treatment of achalasia: an experimental study in dogs.
    Zhu YQ; Cheng YS; Li MH; Zhao JG; Li F; Chen NW
    Neurogastroenterol Motil; 2010 Nov; 22(11):1240-7, e321-2. PubMed ID: 20637056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A highly flexible paclitaxel-loaded poly(ε-caprolactone) electrospun fibrous-membrane-covered stent for benign cardia stricture.
    Zhu Y; Hu C; Li B; Yang H; Cheng Y; Cui W
    Acta Biomater; 2013 Sep; 9(9):8328-36. PubMed ID: 23770223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue hyperplasia: influence of a paclitaxel-eluting covered stent--preliminary study in a canine urethral model.
    Shin JH; Song HY; Choi CG; Yuk SH; Kim JS; Kim YM; Yoon CJ; Kim TH; Suh JY; He X
    Radiology; 2005 Feb; 234(2):438-44. PubMed ID: 15671001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative healing response after sirolimus- and paclitaxel-eluting stent implantation in a pig model of restenosis.
    Silva GV; Fernandes MR; Madonna R; Clubb F; Oliveira E; Jimenez-Quevedo P; Branco R; Lopez J; Angeli FS; Sanz-Ruiz R; Vaughn WK; Zheng Y; Baimbridge F; Canales J; Cardoso CO; Assad JA; Falotico R; Perin EC
    Catheter Cardiovasc Interv; 2009 May; 73(6):801-8. PubMed ID: 19309735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus-eluting stents compared with paclitaxel-eluting stents for treatment of coronary in-stent restenoses.
    Markovic S; Paliskyte R; Rottbauer W; Wöhrle J
    Cardiovasc Revasc Med; 2012; 13(6):307-10. PubMed ID: 23164475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymer-free sirolimus-eluting versus polymer-based paclitaxel-eluting stents: an individual patient data analysis of randomized trials.
    Cassese S; Desch S; Kastrati A; Byrne RA; King L; Tada T; Lauer B; Schömig A; Thiele H; Pache J
    Rev Esp Cardiol (Engl Ed); 2013 Jun; 66(6):435-42. PubMed ID: 24776045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
    Stone GW; Moses JW; Ellis SG; Schofer J; Dawkins KD; Morice MC; Colombo A; Schampaert E; Grube E; Kirtane AJ; Cutlip DE; Fahy M; Pocock SJ; Mehran R; Leon MB
    N Engl J Med; 2007 Mar; 356(10):998-1008. PubMed ID: 17296824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of Rapamycin and Paclitaxel eluting stent in patients with multi-vessel coronary disease].
    Han YL; Wang XZ; Jing QM; Wang SL; Ma YY; Luan B
    Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Feb; 34(2):123-6. PubMed ID: 16626577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study.
    Simsek C; Räber L; Magro M; Boersma E; Onuma Y; Stefanini GG; Zanchin T; Kalesan B; Wenaweser P; Jüni P; van Geuns RJ; van Domburg RT; Windecker S; Serruys PW
    Int J Cardiol; 2013 Dec; 170(1):36-42. PubMed ID: 24196314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of drug-eluting metal stents in benign esophageal stricture: an in vivo animal study.
    Jeon SR; Eun SH; Shim CS; Ryu CB; Kim JO; Cho JY; Lee JS; Lee MS; Jin SY
    Endoscopy; 2009 May; 41(5):449-56. PubMed ID: 19418400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a novel slow-release paclitaxel-eluting stent with a bioabsorbable polymeric surface coating.
    Jabara R; Chronos N; Conway D; Molema W; Robinson K
    JACC Cardiovasc Interv; 2008 Feb; 1(1):81-7. PubMed ID: 19393150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus-eluting stents in the canine cerebral vasculature: a prospective, randomized, blinded assessment of safety and vessel response.
    Levy EI; Hanel RA; Howington JU; Nemes B; Boulos AS; Tio FO; Paciorek AM; Amlani S; Kagan-Hallett KS; Fronckowiak MD; Guterman LR; Hopkins LN
    J Neurosurg; 2004 Apr; 100(4):688-94. PubMed ID: 15070124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammation inhibitory effects of sirolimus and paclitaxel-eluting stents on interleukin-1β-induced coronary artery in-stent restenosis in pigs.
    Zhou XC; Huang RC; Zhang B; Yin D; Liang B; Wang SP; Guan QG; Sun XZ; Miao ZL; He XZ; Han FT; Cheng Y; Zhang L; Zeng DY
    Chin Med J (Engl); 2010 Sep; 123(17):2405-9. PubMed ID: 21034557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
    Caixeta A; Lansky AJ; Serruys PW; Hermiller JB; Ruygrok P; Onuma Y; Gordon P; Yaqub M; Miquel-Hebert K; Veldhof S; Sood P; Su X; Jonnavithula L; Sudhir K; Stone GW;
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1220-8. PubMed ID: 21232715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.